There are currently 18 clinical trials in St Louis, Missouri looking for participants to engage in research studies. Trials are conducted at various facilities, including For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Washington University School of Medicine, Washington University and Siteman Cancer Center at Barnes-Jewish Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Prospective Database of Infants With Cholestasis
NCT00061828
Recruiting
Biliary atresia, idiopathic neonatal hepatitis, and specific genetic cholestatic conditions are the most common causes of jaundice and hyperbilirubinemia that continue beyond the newborn period. The long term goal of the Childhood Liver Disease Research Network (ChiLDReN) is to establish a database of clinical information and plasma, serum, and tissue samples from cholestatic children to facilitate research and to perform clinical, epidemiological and therapeutic trials in these important pediat... Read More
Gender:
ALL
Ages:
6 months and below
Trial Updated:
05/19/2025
Locations: Washington University School of Medicine, St Louis, Missouri
Conditions: Biliary Atresia, Neonatal Cholestasis
Register for Updates
Biliary Atresia Study in Infants and Children
NCT00345553
Recruiting
Little is known about the factors that cause biliary atresia nor the factors that influence disease progression. The purpose of this study is to collect the pertinent clinical information, genetic material and body fluid samples to enable investigators to address the following aims: To identify the gene or genes implicated in the etiology of BA; To identify polymorphisms that may be important in disease progression such as HLA polymorphisms; To characterize the natural history of the older, non-... Read More
Gender:
ALL
Ages:
Between 6 months and 20 years
Trial Updated:
05/19/2025
Locations: Washington University School of Medicine, St Louis, Missouri
Conditions: Biliary Atresia
Register for Updates
The Pediatric Anesthesia Quality Improvement Project
NCT00674388
Recruiting
The Study is designed to collect information about adverse events that occur in children undergoing anesthesia in participating hospitals. Demographic information will be collected on all anesthetics. An analysis of each adverse event will be performed and entered into the database. From this information we will devise strategies to prevent these adverse events.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
05/15/2025
Locations: SSM Cardinal Glennon Health Care System, ST Louis, Missouri
Conditions: Surgery, Anesthesia, Children
Register for Updates
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
NCT06668064
Recruiting
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/01/2025
Locations: The Retina Institute, St Louis, Missouri
Conditions: Wet Age Related Macular Degeneration, wAMD
Register for Updates
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel
NCT05561127
Recruiting
To determine the safety and efficacy of GIE Medical's ProTractX3™ TTS DCB for the treatment of recurrent benign bowel strictures.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
04/24/2025
Locations: Washington University, St Louis, Missouri
Conditions: Bowel; Stricture
Register for Updates
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus
NCT05561114
Recruiting
To evaluate the safety and efficacy of the ProTractX3™ DCB for the treatment of benign esophageal strictures.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
04/24/2025
Locations: Washington University, St Louis, Missouri
Conditions: Esophageal Stricture
Register for Updates
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
NCT05614739
Recruiting
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines that treat cancer. LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and possibly longer if the disease does not get worse.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Washington University School of Medicine, St Louis, Missouri
Conditions: Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
Register for Updates
Rhythm Express Wearable System vs. Simultaneous Polysomnography for the Diagnosis of Obstructive Sleep Apnea in Adults With Suspected or Observed Atrial Fibrillation
NCT06907888
Recruiting
The goal of this observational study is to confirm the accuracy of the sleep algorithm (software) used in the Rhythm Express Wearable System to detect sleep apnea severity. The study involves participants wearing the RX-1 mini cardiac monitor on their chest and a pulse oximeter during a traditional sleep test, known as polysomnography (PSG), conducted in a sleep center. The performance of the device will be evaluated by comparing the results from the Rhythm Express Wearable System with those fro... Read More
Gender:
ALL
Ages:
Between 21 years and 85 years
Trial Updated:
04/15/2025
Locations: Clayton Sleep Institute, St Louis, Missouri
Conditions: Obstructive Sleep Apnea (OSA), Atrial Fibrillation (Paroxysmal), Palpitations
Register for Updates
GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION)
NCT05818150
Recruiting
This multicenter, prospective, interventional trial is designed to assess the outcome of subjects with symptomatic knee osteoarthritis (OA) that are randomized to treatment with either genicular artery embolization (GAE) using Embosphere Microspheres or steroid injection over a period of 24 months.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/03/2025
Locations: Saint Louis University, St Louis, Missouri
Conditions: Knee Osteoarthritis
Register for Updates
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
NCT05531656
Recruiting
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
03/26/2025
Locations: Washington University School of Medicine, St Louis, Missouri
Conditions: Early Alzheimer's Disease
Register for Updates
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients with Vertebral Compression Fractures
NCT04835428
Recruiting
This is a multicenter, single-blinded, randomized controlled clinical trial evaluating the safety and efficacy of the AGN1 LOEP SV Kit for the treatment of painful vertebral compression fragility fractures (VCFs). The objective of this study is to demonstrate non-inferiority of the AGN1 LOEP SV Kit for the treatment of VCFs to standard of care vertebroplasty treatment using bipedicular injection of PMMA bone cement.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/25/2025
Locations: Washington University St. Louis, St Louis, Missouri
Conditions: Vertebral Compression Fracture, Compression Fracture, Vertebral Compression
Register for Updates
A Study of YL201 in Patients with Advanced Solid Tumors
NCT05434234
Recruiting
This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohorts of patients with advanced solid tumors unresponsive to currently available therapies or for whom no standard therapy is available. Part 2 will include patients with selected advanced solid tumor t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Washington University School of Medicine, St Louis, Missouri
Conditions: Advanced Solid Tumor
Register for Updates